Long-term outcome of acquired transthyretin amyloidosis
Acquired ATTR amyloidosis frequently develops in long-term DLT recipients. Although tafamidis stabilizes clinical manifestations in most patients, it may not completely prevent disease progression in some cases. Further long-term evaluation is needed to determine optimal treatment strategies, including siRNA therapy.
Authors
- Masayoshi Tasaki (ORCID: https://orcid.org/0000-0002-9597-4128)
- Yukio Ando (ORCID: https://orcid.org/0000-0002-9050-9710)
- Mitsuharu Ueda (ORCID: https://orcid.org/0000-0002-6814-0582)
- K Obayashi
- Yohei Misumi (ORCID: https://orcid.org/0000-0003-4372-2436)
- Shiori Yamakawa
- Tomoaki Taguchi
- Taro Yamashita
- Toshiya Nomura
Institutions
- Morpho (United States) (US)
- National Sanyo Hospital (JP)
- Department of Physiological Sciences (RU)
- Kawamura Hospital (JP)
- Kumamoto University (JP)
Publication Details
- Journal
- Amyloid
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1080/13506129.2025.2611257
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00